Comparative Pharmacology
Head-to-head clinical analysis: NORETHINDRONE versus PROGESTERONE VAGINAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORETHINDRONE versus PROGESTERONE VAGINAL.
NORETHINDRONE vs Progesterone (Vaginal)
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Norethindrone is a synthetic progestin that binds to progesterone receptors, suppressing gonadotropin (LH and FSH) release from the pituitary, inhibiting ovulation, and inducing secretory changes in the endometrium. It also has weak androgenic and estrogenic activity.
Progesterone binds to progesterone receptors in the reproductive tract, converting proliferative endometrium to secretory endometrium, and reduces gonadotropin secretion, inhibiting ovulation.
5 mg orally once daily for 5 days starting on day 5 of menstrual cycle or 0.35 mg orally once daily for contraception.
For progesterone deficiency (e.g., assisted reproductive technology, luteal phase support): 90 mg intravaginally once daily. For secondary amenorrhea: 45 mg intravaginally every other day for up to 12 doses, then 90 mg if needed. For threatened abortion: 200-400 mg intravaginally once or twice daily.
None Documented
None Documented
Terminal elimination half-life: 5-14 hours (mean 8-10 hours); clinical context: requires once-daily dosing for steady state after ~2 days (5 half-lives).
The terminal elimination half-life of progesterone administered vaginally is approximately 5.5 to 6 hours (range: 4.5–8.0 hours) in women with normal renal and hepatic function. This short half-life necessitates twice-daily dosing for sustained effects.
Renal (30-50% as glucuronide conjugates, 5-10% unchanged), fecal (<10%)
Primarily hepatic metabolism; about 50-60% of metabolites are excreted renally as glucuronide conjugates, with approximately 30-40% eliminated via feces. Less than 1% of unchanged progesterone is excreted in urine.
Category D/X
Category A/B
Progestin
Progestin